Cognitive Issues in Pediatric Multiple Sclerosis

por Portaccio, Emilio, De Meo, Ermelinda, Bellinvia, Angelo, Amato, Maria Pia
Publicado 2021

Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues

por Benedict, Ralph H B, Amato, Maria Pia, DeLuca, John, Geurts, Jeroen J G
Publicado 2020

Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?

por Saposnik, Gustavo, Maurino, Jorge, Sempere, Angel P, Terzaghi, Maria A, Amato, Maria Pia, Montalban, Xavier
Publicado 2019

Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis

por Amato, Maria Pia, De Stefano, Nicola, Inglese, Matilde, Morena, Emanuele, Ristori, Giovanni, Salvetti, Marco, Trojano, Maria
Publicado 2022

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study

por Zanghì, Aurora, Avolio, Carlo, Amato, Maria Pia, Filippi, Massimo, Trojano, Maria, Patti, Francesco, D’Amico, Emanuele
Publicado 2021

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab

por Allinovi, Marco, Cirami, Calogero Lino, Caroti, Leonardo, Antognoli, Giulia, Farsetti, Silvia, Amato, Maria Pia, Minetti, Enrico Eugenio
Publicado 2017

Aggressive multiple sclerosis (1): Towards a definition of the phenotype

por Iacobaeus, Ellen, Arrambide, Georgina, Amato, Maria Pia, Derfuss, Tobias, Vukusic, Sandra, Hemmer, Bernhard, Tintore, Mar, Brundin, Lou
Publicado 2020

Aggressive multiple sclerosis (2): Treatment

por Arrambide, Georgina, Iacobaeus, Ellen, Amato, Maria Pia, Derfuss, Tobias, Vukusic, Sandra, Hemmer, Bernhard, Brundin, Lou, Tintore, Mar
Publicado 2020

Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey

por Portaccio, Emilio, Fonderico, Mattia, Hemmer, Bernhard, Derfuss, Tobias, Stankoff, Bruno, Selmaj, Krzysztof, Tintorè, Mar, Amato, Maria Pia
Publicado 2021

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies

por Bellinvia, Angelo, Aprea, Maria Grazia, Portaccio, Emilio, Pastò, Luisa, Razzolini, Lorenzo, Fonderico, Mattia, Addazio, Ilaria, Betti, Matteo, Amato, Maria Pia
Publicado 2022

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study

por Patti, Francesco, Morra, Vincenzo Brescia, Amato, Maria Pia, Trojano, Maria, Bastianello, Stefano, Tola, Maria Rosalia, Cottone, Salvatore, Plant, Andrea, Picconi, Orietta
Publicado 2013

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion

por Filippi, Massimo, Amato, Maria Pia, Centonze, Diego, Gallo, Paolo, Gasperini, Claudio, Inglese, Matilde, Patti, Francesco, Pozzilli, Carlo, Preziosa, Paolo, Trojano, Maria
Publicado 2022

Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion

por Filippi, Massimo, Amato, Maria Pia, Centonze, Diego, Gallo, Paolo, Gasperini, Claudio, Inglese, Matilde, Patti, Francesco, Pozzilli, Carlo, Preziosa, Paolo, Trojano, Maria
Publicado 2022

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGniti...

por Bastianello, Stefano, Giugni, Elisabetta, Amato, Maria Pia, Tola, Maria-Rosalia, Trojano, Maria, Galletti, Stefano, Luccichenti, Giacomo, Quarantelli, Mario, Picconi, Orietta, Patti, Francesco
Publicado 2011

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG

por Waubant, Emmanuelle, Banwell, Brenda, Wassmer, Evangeline, Sormani, Maria-Pia, Amato, Maria-Pia, Hintzen, Rogier, Krupp, Lauren, Rostásy, Kevin, Tenembaum, Silvia, Chitnis, Tanuja
Publicado 2019

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4

por Centonze, Diego, Amato, Maria Pia, Brescia Morra, Vincenzo, Cocco, Eleonora, De Stefano, Nicola, Gasperini, Claudio, Gallo, Paolo, Pozzilli, Carlo, Trojano, Maria, Filippi, Massimo
Publicado 2023

Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis

por Rossi, Francesca, Giorgio, Antonio, Battaglini, Marco, Stromillo, Maria Laura, Portaccio, Emilio, Goretti, Benedetta, Federico, Antonio, Hakiki, Bahia, Amato, Maria Pia, De Stefano, Nicola
Publicado 2012

Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of...

por Bertoli, Diego, Serana, Federico, Sottini, Alessandra, Cordioli, Cinzia, Maimone, Davide, Amato, Maria Pia, Centonze, Diego, Florio, Ciro, Puma, Elisa, Capra, Ruggero, Imberti, Luisa
Publicado 2015

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis

por De Stefano, Nicola, Stromillo, Maria Laura, Giorgio, Antonio, Bartolozzi, Maria Letizia, Battaglini, Marco, Baldini, Mariella, Portaccio, Emilio, Amato, Maria Pia, Sormani, Maria Pia
Publicado 2016

Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis

por Fonderico, Mattia, Portaccio, Emilio, Razzolini, Lorenzo, Pastò, Luisa, Bellinvia, Angelo, Addazio, Ilaria, Betti, Matteo, Aprea, Maria Grazia, Ballerini, Clara, Biagioli, Tiziana, Amato, Maria Pia
Publicado 2021